Skip to content
TrialScanner

NCT04314934

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

Phase 2/Phase 3CompletedAVXLLead

Registry record

Lead sponsor
Anavex Life Sciences Corp.
Conditions
Alzheimer Disease
Primary completion
Jun 14, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04314934 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04314934: OLE of Phase 2b/3 Study... | TrialScanner